skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Sevelamer as a phosphate binder in adult hemodialysis patients: an evidence-based review of its therapeutic value

Review

(2791) Views  (1143) Full article downloads

Authors: Carole Nadin

Published Date March 2005 Volume 2005:1-Issues 1 & 2(1) Pages 0 - 0
DOI: http://dx.doi.org/10.2147/CE.S6407

Carole Nadin

Core Medical Publishing, Knutsford, UK

Introduction: Patients on hemodialysis require phosphate binders to reduce dietary phosphate absorption and control serum phosphate. The standard therapy, calcium salts, can be associated with elevated serum calcium (hypercalcemia). Concern has been raised that hypercalcemia, especially combined with elevated serum phosphate, may be associated with arterial calcification, and this may contribute to increased risk of cardiovascular mortality and morbidity. Sevelamer is a nonmetal, nonabsorbed phosphate binder.

Aims: This review assesses the evidence for the therapeutic value of sevelamer as a phosphate binder in adult hemodialysis patients.

Evidence review: Strong evidence shows that sevelamer is as effective as calcium salts in controlling serum phosphate and calcium–phosphate product, has less risk of inducing hypercalcemia and is more effective at lowering lipid levels. Some evidence indicates that sevelamer reduces arterial calcification progression and loss of bone mineral density, but it may be more likely to induce metabolic acidosis, compared with calcium salts. Sevelamer-containing regimens may improve calcific uremic arteriolopathy, although the evidence is weak. Evidence is divided on whether the incidence of gastrointestinal adverse events with sevelamer is similar to or higher than that with calcium salts. Retrospective and modeling studies suggest lower cardiovascular morbidity and mortality with sevelamer than with calcium salts, with incremental cost-effectiveness of $US1100–2200 per life-year gained. Further direct evidence is needed on mortality, quality of life, and cost-effectiveness.

Place in therapy: Sevelamer is effective in controlling serum phosphate and lowering lipid levels in hemodialysis patients without inducing hypercalcemia, and may have beneficial effects on arterial calcification.

Key words: sevelamer, calcium salts, phosphate binder, hemodialysis, chronic kidney disease, evidence






 

Other articles by Dr Core Journal

Aliskiren in hypertension: evidence for its potential therapeutic value
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
Aripiprazole: the evidence of its therapeutic impact in schizophrenia
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
Bortezomib: the evidence of its clinical impact in multiple myeloma
Ciclesonide in persistent asthma: the evidence of its therapeutic value
Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia
Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia
Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction
Etanercept in psoriasis: the evidence of its therapeutic impact
Exubera® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes
Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value
K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome
Lapatinib: the evidence for its therapeutic value in metastatic breast cancer
Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
Maraviroc: the evidence for its potential in the management of HIV
Perindopril: the evidence of its therapeutic impact in hypertension
Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
Tigecycline: an evidence-based review of its antibacterial activity and effectiveness in complicated skin and soft tissue and intraabdominal infections
Topiramate: the evidence for its therapeutic value in the prevention of migraine
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus


Readers of this article also read:

Should patients set the agenda for informed, consent? A prospective survey of desire for information and discussion prior to routine cataract surgery
Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
Top-down or bottom-up: Contrasting perspectives on psychiatric diagnoses
"Globalized public health.” A transdisciplinary comprehensive framework for analyzing contemporary globalization’s influences on the field of public health
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
Update and critical appraisal of sevelamer in the management of chronic renal failure
Wearing facemasks when performing lumbar punctures: a snapshot of current practice amongst trainee doctors
Molecular mechanisms of hyperglycemia and cardiovascular-related events in critically ill patients: rationale for the clinical benefits of insulin therapy
Subgroup analysis of large trials can guide further research: a case study of vitamin E and pneumonia
A case of recurrent bloody tears
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University